Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedDifference0.2%
- Check31 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check38 days agoChange DetectedThe website has updated the contact details section for the study, now providing clearer information on who to contact for questions and where the study is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check53 days agoChange DetectedThe website has added a 'Show less' option, while several detailed data fields and options related to participant groups, interventions, and study details have been removed.SummaryDifference3%
- Check67 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading study data in various formats and displaying detailed participant and study information, while removing the 'Show less' option and the previous version v2.12.1.SummaryDifference3%
Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.